Skip to main content

Advertisement

SpringerLink
Log in

Migraine with aura: conventional and non-conventional treatments

  • Treatment
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Migraine with aura (MwA) is a primary headache that affects up 30% of migraine patients. Although the frequency of MwA attacks is usually low and the majority of migraine sufferers do not need prophylactic treatment(s), same particular patients do. This occurs when the neurological symptoms, that characterize the auras, determine anxiety to the migraine sufferers and when the frequency of MwA attacks is or becomes high. In this study, we review the few therapeutic conventional options specifically devoted to cure MwA attacks present in the literature together with those, recent, non-conventional.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and characteristics of migraine in a population based cohort: the GEM study. Neurology 53:537–542

    PubMed  CAS  Google Scholar 

  2. Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(suppl 7):1–96

    Google Scholar 

  3. Stewart WF, Schechter A, Lipton RB (1994) Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 44(suppl 4):24–39

    Google Scholar 

  4. Leao AAP (1944) Spreading depression of activity of cerebral cortex. J Neurophysiol 7:279–390

    Google Scholar 

  5. Olesen J, Larsen B, Luritzen M (1981) Focal hyperemia followed by spreading olegimia an impaired activation of rCBF in classic migraine. Ann Neurol 14:344–352

    Article  Google Scholar 

  6. D’Andrea G, Leon A (2010) Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurolo Sci 31(Suppl 1):S1–S7

    Article  Google Scholar 

  7. Aurora KS, Cao Y, Bowyer SM, Welch KMA (1999) The occipital cortex is hyperexcitable inmigraine: experimental evidences. Headache 39(7):469–476

    Article  PubMed  CAS  Google Scholar 

  8. Lang E, Kaltenhauser M, Neundorfer B, Seidler S (2004) Hyperexcitability of the primary somatosensory cortex in migraine-a magnetoencephlographic study. Brain 127:2459–2469

    Article  PubMed  Google Scholar 

  9. Welch KMA (1987) Migraine. A biobehavioral disorder. Arch Neurol 44:1899–1987

    Google Scholar 

  10. Mangano RM, Schwarcz R (1981) The human platelet as a model for the glutamatergic neuron: platelt uptake of l-glutamate. J Neurochem 36(3):1067–1076

    Article  PubMed  CAS  Google Scholar 

  11. D’Andrea G, Cananzi AR, Joseph R, Morra M, Zamberlan F, Ferro Milone F, Grunfeld S, Welch KMA (1991) Platelet glycine glutamate and aspartate in primary headache glutamate and aspartate in primary headache. Cephalalgia 11:197–200

    Article  PubMed  Google Scholar 

  12. Cananzi AR, D’Andrea G, Perini F, zamberlan F, Welch KMA (1995) Plasma and platelet levels of glutamate and glutamine in migraine with and without aura. Cephalagia 15:132–135

    Article  CAS  Google Scholar 

  13. Prescot A, Becerra L, Pendse G, tully S, Burnstein R et al (2009) Excitatory neurotransmitters in brain regions in the interictal migraine patients. Mol Pain 5:34

    Article  PubMed  Google Scholar 

  14. D’Andrea G, Toldo M, Cortelazzo S, Ferro Milone F (1982) Platelet activity in migraine. Hedache 22:207–212

    Article  Google Scholar 

  15. D’Andrea G, Hasselmark L, Alecci M, Cananzi AR, Perini F, Welch KMA (1994) Platelet secretion from dense and α-granules in vitro in migraine with and without aura. J Neurol Neurosurg Psychiatry 57(5):557–561

    Article  PubMed  Google Scholar 

  16. Joseph R, Welch KMA, D’Andrea G, Levine SR (1987) Sensitivity to PAF is increased inmigraine patients. Thromb Haemost 57:125

    PubMed  CAS  Google Scholar 

  17. Sarchielli P, Alberti A, Coppola F, Baldi A, Gallai B, Floridi A, Capocchi G, Gallai V (2004) Platelet activating factor (PAF) in internal jugualr venous blood of migraine without aura assessed during migraine attacks. Cephalagia 24:623–630

    Article  CAS  Google Scholar 

  18. D’Andrea G, Cananzi AR, Perini F, Hasselmark L (1995) Platelet models and their possible usefulness in study of migraine pathogenesis. Cephalalgia 15:265–271

    Article  PubMed  Google Scholar 

  19. Anzola GP, Magoni M, Guindani M et al (1999) Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 52:1622–1625

    PubMed  CAS  Google Scholar 

  20. Carrerj S, Narbone MC, Zito C, serra S, Coglitore S, Pugliatti P, Luz Arrigo F, Oreto G (2003) Prevalence of atrial septum aneurysm in patients with migraine echocardiographic study. Headache 43((7):725–728

    Article  Google Scholar 

  21. D’Andrea G, Bonavita V, Rigamonti A, Bussone G (2003) Treatment of migraine with aura: comments and prospectives. Neurol Sci 23:271–278

    Article  PubMed  Google Scholar 

  22. Montagna P, Sacquegna T, Cortelli P, Lugaresi E (1989) Migraine as defect of brain oxidative metabolism: a hypothesis. J Neurol 236:124–125

    Article  PubMed  CAS  Google Scholar 

  23. Jensen K, Tfelt Hansen P, Lauritzen M, Olesen J (1985) Clinical trial of nimodipine for single attacks of classical migraine. Cephalalgia 5:125–131

    Article  PubMed  Google Scholar 

  24. Goldner JA, Lewitt LP (1987) Treatment of complicated migraine with sublingual nifedipine. Headache 27:484–486

    Article  PubMed  CAS  Google Scholar 

  25. Banerjee M, Findley LJ (1992) Sumatriptan in the treatment of acute migraine with aura. Cephalalgia 12:39–44

    Article  PubMed  CAS  Google Scholar 

  26. Bates D, Ashford E, Dowson R, Ensink FBM, Gilhus NE, Olesen J, Pilgrim AJ, Shvelin P (1994) Sumatriptan Aura Study Group. subcutaneous sumatriptan during the migraine aura. Neurology 44:1587–1592

    PubMed  CAS  Google Scholar 

  27. Hachinsky V, Norris JW, Edmeads J, Cooper PW (1978) Ergotamine and cerebral blood flow. Stroke 9:594–596

    Google Scholar 

  28. Sanches del Rio M, Bakker D, O Wu et al (1999) Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 19(8):701–707

    Article  Google Scholar 

  29. Henry PY, Larre P, Aupy M, Lafforgue JL, Orgogozo JM (1984) Reversible cerebral arteriopathy associated with the administration of ergot derivatives. Cephalalgia 4:171–178

    Article  PubMed  CAS  Google Scholar 

  30. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC (2000) Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55:139–141

    PubMed  CAS  Google Scholar 

  31. Rozen DT (2000) Treatment of prolonged migrainous aura with intravenous furosemide. Neurology 55:732–733

    PubMed  CAS  Google Scholar 

  32. Haan J, Sluis P, Sluis LH, Ferrari MD (2000) Acetazolamide treatment for migraine aura status. Neurology 55:1588–1589

    PubMed  CAS  Google Scholar 

  33. Cologno D, Torelli P, Cademartiri C, Manzoni GC (2000) A prospective study of migraine with aura attacks in a headache clinic population. Cephalalgia 20(10):925–930

    Article  PubMed  CAS  Google Scholar 

  34. Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Nyagaard Kristensen T, de Fine Olivarius B (1983) Prophylactic treatment of classical and non classical migraine with metoprolol a comparison with placebo. Cephalalgia 3:207–212

    Article  PubMed  CAS  Google Scholar 

  35. Kangasniemi P, Andersen AR, Andresson PG, Gilhus NE, Hedman C, Hultren M, Vilming S, Olesen J (1987) Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 7(4):231–238

    Article  PubMed  CAS  Google Scholar 

  36. Kangasniemi P, Hedman C (1984) Metoprolol and propranolol in the prophylactic treatment of classical and common migraine: a double-blind study. Cephalalgia 4:91–96

    Article  PubMed  CAS  Google Scholar 

  37. Hedman C, Andressen AR, Andresson PG, Gilhus NE, Kangasniemi P, Olsson JE, Strandman E, Nestvold K, Olesen J (1988) Symptoms of classic migraine attacks: modifications brought about by metoprolol. Cephalalgia 8:279–284

    Article  PubMed  CAS  Google Scholar 

  38. Mentenopoulos G, Manafi TH, Logothetis J, Bostantzopoulou S (1985) Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 5(Suppl 2):134–140

    Google Scholar 

  39. D’Andrea G, Nordera GP (2006) Allais G Treatment of aura: solving the puzzle Neurol Sci 27(Suppl 2):S96–S99

    Google Scholar 

  40. D’Andrea G, Granella F, Cadaldini M, Manzoni GC (1999) Effectiveness of lamotrigine in the prophylaxis. Cephalalgia 19:64–66

    Article  PubMed  Google Scholar 

  41. Lampl C, Buzath A, Klinger D, Neumann K (1999) Lamotrigine in the prophylactic treatment of migraine with aura: a pilot study. Cephalalgia 19:58–63

    Article  PubMed  CAS  Google Scholar 

  42. Chen WT, Fuh JL, Lu SR, Wang SJ (2001) Persistent migraineous visual phenomena might be responsive to lamotrigine. Headache 41:823–825

    Article  PubMed  CAS  Google Scholar 

  43. D’Andrea G, Granella F, Verdelli F (2002) Migraine with aura triggered by orgasm. Cephalalgia 22(6):485–486

    Article  PubMed  Google Scholar 

  44. Pascual J, Caminero AB, Mateos V, Roig C, Leira R, Garcia-Monco C, Lainez MJ (2004) Preventing disturbing migraine with aura with lamotrigine: an open pilot study. Headache 44:1024–1028

    Article  PubMed  Google Scholar 

  45. Lampl C, Katsarava Z, Diener HC, Limmroth V (2006) Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 76:1730–1732

    Article  Google Scholar 

  46. Steiner TJ, Findley LJ, Yeun AWC (1997) Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalagia 17:109–112

    Article  CAS  Google Scholar 

  47. White HS, Brown Sd, Woodhead JH, Skeen GA, Wolf HH (1997) Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28:167–179

    Article  PubMed  CAS  Google Scholar 

  48. Cutrer FM (2001) Antiepileptic drugs: how they work in headache. Headache 41(Suppl 1):3–10

    Article  Google Scholar 

  49. Lampl C, Bonelli S, Ramsmayr G (2004) Efficacy of topiramate in migraine with aura prophylaxis: preliminary results of 12 patients. Headache 44:174–177

    Article  PubMed  Google Scholar 

  50. Modesti PA, Colella A, Gensini G, Neri Serneri G (1989) Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol 169(1):85–93

    Article  PubMed  CAS  Google Scholar 

  51. Allais G, D’Andrea G, Airola G, De Lorenzo C, Mana O, Benedetto C (2004) Picotamide in Migraine with aura prevention: a pilot study. Neurol Sci 25(Suppl 3):S267–S269

    Article  PubMed  Google Scholar 

  52. Wang SJ, Chen HH (2005) Ginkgolide b, a constituent of Ginkgo Biloba, facilitates glutamate exocytosis from rat hippocampal nerve terminal. Eur J Pharmacol 514:141–149

    PubMed  CAS  Google Scholar 

  53. Kuribara K, Wardlaw AJ, Moqbel R, Kay AB (1989) Inhibition of platelet-activating factor (PAF) banding to human eosinophils and neutrophils by specific Ginkgolide-derived PAF antagonist BN52021. J Allergy Clin Immunol 83:83–90

    Article  Google Scholar 

  54. Teather LA, Afonso VM, Wurtman RJ (2006) Inhibition of platelet-activating factor receptors in hippocampal plasma membranes attenuates the inflammatory nociceptive response in rats. Brain Res 1097(1):230–233

    Article  PubMed  CAS  Google Scholar 

  55. Xia SH, Fang DC (2007) Pharmacological action and mechanism of ginlgolide. Clin Med J 120(10):922–928

    CAS  Google Scholar 

  56. Joseph R, Welch KM, D’Andrea G, Levine SR (1987) Sensitivity to PAF is increased inmigraine patients. Thromb Haemost 57(1):125

    PubMed  CAS  Google Scholar 

  57. D’Andrea G, Hasselmak L, Alecci M, Cananzi AR, Perini F, Welch KMA (1994) Platelet secretion from dense and α-granules in vitro in migraine with and without aura. J Neurosurg Psychiatry 57(5):557–561

    Article  Google Scholar 

  58. Sarchielli P, Alberti A, Coppola F, Baldi A, Gallai B, Floridi A, Capecchi G, Gallai V (2004) Platelet-activating factor (PAF) in internal jugular venous blood of migraine with and without Aura patients assessed during migraine attacks. Cephalalgia 24:623–630

    Article  PubMed  CAS  Google Scholar 

  59. Perini F, D’Andrea G, Galloni E et al (2005) Plasma cytochine levels in migraineurs and controls. Headache 45:926–931

    Article  PubMed  Google Scholar 

  60. Yoshikawa T, Nalto Y, Kondo M (1999) Gingko biloba leaf extract: review of biological action and clinical applications. Antioxid Redox Signal 1(4):469–480

    Article  PubMed  CAS  Google Scholar 

  61. Welch KM, Nagesh V, Aurora SK et al (2001) Periacquetuctal gay matter disfunction in migraine: cause or the burden of illness? Headache 7:629–637

    Article  Google Scholar 

  62. Thompson AJ, Jarvis GE, Duke RK, Johnston GA, Lummis SC (2011) Gingkolide b and bilolabide block the pore of the 5-HT3 receptor at a location that overlap the picrotoxin binding site. Neuropharmacology 60(2–3):488–495

    Google Scholar 

  63. Faris LP, Eckert DE, Kim Suck-Von, Meller HW, Pardo VJ, Goodale LR, Hartman KB (2006) Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J Affect Disord 92:79–90

    Article  PubMed  Google Scholar 

  64. The International Classification of Headache Disorders (2004) 2nd edn. Cephalalgia 24(suppl-1):1–160

    Google Scholar 

  65. D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Peretta V, Benedetto C (2009) Efficacy of Ginkolide b in the Prophylaxis of migraine with aura. Neurol Sci 30(Suppl 1):S121–S124

    Article  PubMed  Google Scholar 

  66. Evers S, Afra J, Frese A, Goasdsby J, Linde M, May A, Sandor PS (2009) EFNS guideline on the drug treatment of migraine revised report of an EFNS task force. Eur J Neurol 16:968–998

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Biochemistry Laboratory for the Study of Primary Headaches and Neurological Degenerative Diseases, Research and Innovation (R&I), Padova, Italy

    Giovanni D’Andrea, Davide Colavito, Maurizio Dalle Carbonare & Alberta Leon

Authors
  1. Giovanni D’Andrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davide Colavito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maurizio Dalle Carbonare
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberta Leon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni D’Andrea.

Rights and permissions

Reprints and permissions

About this article

Cite this article

D’Andrea, G., Colavito, D., Dalle Carbonare, M. et al. Migraine with aura: conventional and non-conventional treatments. Neurol Sci 32 (Suppl 1), 121–129 (2011). https://doi.org/10.1007/s10072-011-0529-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-011-0529-0

Keywords

Search

Navigation